Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Sio Gene Therapies Inc is a biotechnology business based in the US. Sio Gene Therapies shares (SIOX) are listed on the NASDAQ and all prices are listed in US Dollars. Sio Gene Therapies employs 42 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$2.22|
|52-week range||$1.76 - $3.95|
|50-day moving average||$2.16|
|200-day moving average||$2.33|
|Wall St. target price||$7.40|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.60|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||1.83%|
|1 month (2021-09-15)||0.45%|
|3 months (2021-07-15)||-4.72%|
|6 months (2021-04-15)||-10.12%|
|1 year (2020-10-15)||-35.47%|
|2 years (2019-10-15)||-61.53%|
|3 years (2018-10-15)||2.37|
|5 years (2016-10-14)||13|
|Gross profit TTM||$0|
|Return on assets TTM||-28.7%|
|Return on equity TTM||-41.54%|
|Market capitalisation||$159 million|
TTM: trailing 12 months
There are currently 1.5 million Sio Gene Therapies shares held short by investors – that's known as Sio Gene Therapies's "short interest". This figure is 17.7% down from 1.8 million last month.
There are a few different ways that this level of interest in shorting Sio Gene Therapies shares can be evaluated.
Sio Gene Therapies's "short interest ratio" (SIR) is the quantity of Sio Gene Therapies shares currently shorted divided by the average quantity of Sio Gene Therapies shares traded daily (recently around 707140.47619048). Sio Gene Therapies's SIR currently stands at 2.1. In other words for every 100,000 Sio Gene Therapies shares traded daily on the market, roughly 2100 shares are currently held short.
However Sio Gene Therapies's short interest can also be evaluated against the total number of Sio Gene Therapies shares, or, against the total number of tradable Sio Gene Therapies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sio Gene Therapies's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Sio Gene Therapies shares in existence, roughly 20 shares are currently held short) or 0.0306% of the tradable shares (for every 100,000 tradable Sio Gene Therapies shares, roughly 31 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sio Gene Therapies.
Find out more about how you can short Sio Gene Therapies stock.
We're not expecting Sio Gene Therapies to pay a dividend over the next 12 months.
Over the last 12 months, Sio Gene Therapies's shares have ranged in value from as little as $1.76 up to $3.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sio Gene Therapies's is 1.6593. This would suggest that Sio Gene Therapies's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Sio Gene Therapies, Inc. , a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The company develops AXO-Lenti-PD, in vivo lentiviral gene therapy, which is in Phase II clinical trials for the treatment of Parkinson's disease; AXO-AAV-GM1, an investigational gene therapy , which is in Phase I/II clinical trials for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2, an investigational gene therapy, which is in Phase I/II clinical trials for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.